Michael P DiGiovanna, MD, PhD

Associate Professor of Medicine (Medical Oncology)

Physician Biography

Dr. DiGiovanna is a native of Long Island, NY, who graduated from Cornell University in 1984 with a B.A. and a double major in the fields of biochemistry and music. He attended Yale University from 1984 through 1990 where he was earned the MD and PhD degrees, with his PhD in Pharmacology. He continued his post-graduate training at Yale, performing internship and residency in Internal Medicine, a research post-doctoral fellowship, and a clinical fellowship in Medical Oncology. He is currently an attending physician in Medical Oncology and Associate Professor of Medicine (Oncology) and Pharmacology at Yale University. His clinical specialty is breast cancer and he conducts both clinical and laboratory-based research. His translational laboratory research is focused on signal transduction in breast cancer. He also has a leadership role in education at the Yale School of Medicine, including current roles as Director of Pharmacology Curriculum and Director of Modules (clinical pathophysiology courses).

Clinical Interests

  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Breast Cancer Program

Medical Oncology: Subset Medical Oncology Faculty

Yale Medical Group

Board Certifications

  • Medical Oncology AB of Internal Medicine (1997)

Clinical Trials

Conditions Study Title
Breast - Female, Breast - Male Phase II trial of MK-3475 as Monotherapy for mTNBC
Breast - Female Randomized study comparing MPDL3280A with Nab-Paclitaxel compared to placebo with Nab-Paclitaxel
Breast - Female GDC0810 in Postmenopausal Women w/ Locally Advanced/Metastatic Estrogen Recep Positive breast cancer
Breast - Female, Breast - Male Olaparib as Adjuvant Treatment in Patients With BRCA Mutated High Risk HER2 Negative breast cancer
Breast - Female, Breast - Male MM-302 Plus Trastuzumab vs. Chemotherapy Plus Trastuzumab in HER2-positive MBC
Breast - Female Neoadj ph 2 AI plus everolimus in postmenopausal women w/ ER pos/HER2 neg, low risk score
Breast - Female, Breast - Male Phase 2, Randomized, open label study of Lucitanib in FGF abberrant metastatic breast cancer
Breast - Female, Breast - Male Phase II with Orteronel as Monotherapy for Metastatic Breast Cancer that expresses Androgen Receptor
Breast - Female Phase I Study of SGN-LIV1A via IV Infusion in Patients with LIV-1-positive Metastatic Breast Cancer
Breast - Female, Breast - Male S1207 Phase 3 Rand, Adj Endocrine Tx plus Everolimus in High risk ER/PR + HER2neg BC
Anus, Bladder, Breast - Female, Breast - Male, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Liver, Lung, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs Phase I with GDC-0032 for Tx of Local Advanced or Metastatic Solid Tumors or HER2+ Breast Cancer
Breast - Female Neo-Adj, Phase 2, Pertuzumab and Trastuzumab with weekly Paclitaxel and FEC, HER2-pos Breast Cancer
Breast - Female, Breast - Male Breast Cancer Molecular Analysis Prior to Investigational Therapy (MAP-IT)

Edit this profile

Contact Info

Michael P DiGiovanna, MD, PhD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste NP - 1

New Haven, CT 06510
View on map...
Mailing Address
PO Box 208032
300 George Street

New Haven, CT 06520-8032